Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BEHAV3D: a 3D live imaging platform for comprehensive analysis of engineered T cell behavior and tumor response.
Alieva M, Barrera Román M, de Blank S, Petcu D, Zeeman AL, Dautzenberg NMM, Cornel AM, van de Ven C, Pieters R, den Boer ML, Nierkens S, Calkoen FGJ, Clevers H, Kuball J, Sebestyén Z, Wehrens EJ, Dekkers JF, Rios AC. Alieva M, et al. Among authors: sebestyen z. Nat Protoc. 2024 Jul;19(7):2052-2084. doi: 10.1038/s41596-024-00972-6. Epub 2024 Mar 19. Nat Protoc. 2024. PMID: 38504137 Review.
CRISPR screens decode cancer cell pathways that trigger γδ T cell detection.
Mamedov MR, Vedova S, Freimer JW, Sahu AD, Ramesh A, Arce MM, Meringa AD, Ota M, Chen PA, Hanspers K, Nguyen VQ, Takeshima KA, Rios AC, Pritchard JK, Kuball J, Sebestyen Z, Adams EJ, Marson A. Mamedov MR, et al. Among authors: sebestyen z. Nature. 2023 Sep;621(7977):188-195. doi: 10.1038/s41586-023-06482-x. Epub 2023 Aug 30. Nature. 2023. PMID: 37648854 Free PMC article.
Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells.
Hernández-López P, van Diest E, Brazda P, Heijhuurs S, Meringa A, Hoorens van Heyningen L, Riillo C, Schwenzel C, Zintchenko M, Johanna I, Nicolasen MJT, Cleven A, Kluiver TA, Millen R, Zheng J, Karaiskaki F, Straetemans T, Clevers H, de Bree R, Stunnenberg HG, Peng WC, Roodhart J, Minguet S, Sebestyén Z, Beringer DX, Kuball J. Hernández-López P, et al. Among authors: sebestyen z. Nat Immunol. 2024 Jan;25(1):88-101. doi: 10.1038/s41590-023-01665-0. Epub 2023 Nov 27. Nat Immunol. 2024. PMID: 38012415
Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1.
Cornel AM, van der Sman L, van Dinter JT, Arrabito M, Dunnebach E, van Hoesel M, Kluiver TA, Lopes AP, Dautzenberg NMM, Dekker L, van Rijn JM, van den Beemt DAMH, Buhl JL, du Chatinier A, Barneh F, Lu Y, Lo Nigro L, Krippner-Heidenreich A, Sebestyén Z, Kuball J, Hulleman E, Drost J, van Heesch S, Heidenreich OT, Peng WC, Nierkens S. Cornel AM, et al. Among authors: sebestyen z. J Immunother Cancer. 2024 Mar 21;12(3):e007538. doi: 10.1136/jitc-2023-007538. J Immunother Cancer. 2024. PMID: 38519054 Free PMC article.
Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML.
Lo Presti V, Meringa A, Dunnebach E, van Velzen A, Moreira AV, Stam RW, Kotecha RS, Krippner-Heidenreich A, Heidenreich OT, Plantinga M, Cornel A, Sebestyen Z, Kuball J, van Til NP, Nierkens S. Lo Presti V, et al. Among authors: sebestyen z. J Immunother Cancer. 2024 Apr 5;12(4):e008174. doi: 10.1136/jitc-2023-008174. J Immunother Cancer. 2024. PMID: 38580329 Free PMC article.
Serpin B9 controls tumor cell killing by CAR T cells.
Kimman T, Slomp A, Martens A, Grabherr S, Li S, van Diest E, Meeldijk J, Kuball J, Minnema MC, Eldering E, Bovenschen N, Sebestyén Z, Peperzak V. Kimman T, et al. Among authors: sebestyen z. J Immunother Cancer. 2023 Mar;11(3):e006364. doi: 10.1136/jitc-2022-006364. J Immunother Cancer. 2023. PMID: 36931661 Free PMC article.
Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit.
Johanna I, Daudeij A, Devina F, Nijenhuis C, Nuijen B, Romberg B, de Haar C, Haanen J, Dolstra H, Bremer E, Sebestyen Z, Straetemans T, Jedema I, Kuball J. Johanna I, et al. Among authors: sebestyen z. Immunooncol Technol. 2023 Oct 14;20:100411. doi: 10.1016/j.iotech.2023.100411. eCollection 2023 Dec. Immunooncol Technol. 2023. PMID: 38192616 Free PMC article. Review.
Uncovering the mode of action of engineered T cells in patient cancer organoids.
Dekkers JF, Alieva M, Cleven A, Keramati F, Wezenaar AKL, van Vliet EJ, Puschhof J, Brazda P, Johanna I, Meringa AD, Rebel HG, Buchholz MB, Barrera Román M, Zeeman AL, de Blank S, Fasci D, Geurts MH, Cornel AM, Driehuis E, Millen R, Straetemans T, Nicolasen MJT, Aarts-Riemens T, Ariese HCR, Johnson HR, van Ineveld RL, Karaiskaki F, Kopper O, Bar-Ephraim YE, Kretzschmar K, Eggermont AMM, Nierkens S, Wehrens EJ, Stunnenberg HG, Clevers H, Kuball J, Sebestyen Z, Rios AC. Dekkers JF, et al. Among authors: sebestyen z. Nat Biotechnol. 2023 Jan;41(1):60-69. doi: 10.1038/s41587-022-01397-w. Epub 2022 Jul 25. Nat Biotechnol. 2023. PMID: 35879361 Free PMC article.
75 results